Search
Odesivimab
go.drugbank.com/drugs/DB15900ApprovedInvestigationalINMAZEB™ is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020.[L17320] … Ebola virus (EBOV) remains an important human pathogen within the _Ebolavirus_ genus, having been responsible for at least 17 known outbreaks with an average case fatality rate of 43.92%.
Testosterone cypionate
go.drugbank.com/drugs/DB13943ApprovedInvestigationalIt was developed by the company Pharmacia and Upjohn and FDA approved on July 25, 1979. … Testosterone cypionate is a synthetic derivative of testosterone in the form of an oil-soluble 17 (beta)-cyclopentylpropionate ester.
Remdesivir
go.drugbank.com/drugs/DB14761ApprovedInvestigationalLike other RNA viruses, SARS-CoV-2 depends on an RNA-dependent RNA polymerase (RdRp) enzyme complex for genomic replication, which can be inhibited by a class of drugs known as nucleoside analogues. … is the causative agent of coronavirus disease 2019 (COVID-19), which is a respiratory disease that is capable of progressing to viral pneumonia and acute respiratory distress syndrome (ARDS); COVID-19 can
Belimumab
go.drugbank.com/drugs/DB08879ApprovedInvestigationalIt is produced by recombinant DNA technology in a murine cell (NS0) expression system. … [A251495, L42705] By binding to BLyS and blocking its interaction with B cell receptors, belimumab inhibits the survival of B cells.
Choline salicylate
go.drugbank.com/drugs/DB14006ApprovedNutraceuticalThe UK government has regulated its use, due to toxicity in those under 16 years of age. … This medicine can also be used for fever [L2129]. Choline Salicylate is the choline salt of salicylic acid, used as an analgesic, antipyretic and antirheumatic.
Infigratinib
go.drugbank.com/drugs/DB11886ApprovedInvestigationalWithdrawnan FDA-approved test. … By inhibiting the FGFR pathway, which is often aberrated in cancers such as cholangiocarcinoma, infigratinib suppresses tumour growth.
Durlobactam
go.drugbank.com/drugs/DB16704ApprovedInvestigational[L47336] The combination product of durlobactam and sulbactam was first approved by the FDA in May 2023. … It is typically given in combination with [sulbactam] to protect it from degradation by certain serine-beta-lactamases.
Amivantamab
go.drugbank.com/drugs/DB16695ApprovedInvestigationalnon-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based … [A235133] Amivantamab was granted FDA approval on 21 May 2021,[L34193] followed by the approval by the EMA on 9 December 2021 [L41474] and Health Canada on 30 March 2022.
Caplacizumab
go.drugbank.com/drugs/DB06081ApprovedInvestigationalCaplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019,[L5302] and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression … Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker.
Ivosidenib
go.drugbank.com/drugs/DB14568ApprovedInvestigational[L46287] It was fully approved by the EMA in May 2023.[L46596] … IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation.